Valeant To Buy Dendreon’s Never-Was Cancer Vaccine Provenge
This article was originally published in The Pink Sheet Daily
Executive Summary
The dealmaking machine has proposed buying Dendreon’s assets, including prostate cancer immunotherapy Provenge, through a bankruptcy rummage sale.
You may also be interested in...
Deal Watch: Pfizer Circles Allergan, Which Continues Its Own M&A
Allergan remains active, acquiring EU rights to Ironwood's linaclotide from Spain's Almirall. Novartis adds to its immuno-oncology pipeline with Admune purchase, it third I-O transaction in the past month.
Biopharma Quarterly Dealmaking Statistics, Q1 2015
Biopharma financing reached $15.1 billion, with record-breaking FOPO dollar volume making up close to $10 billion of the total; AbbVie topped the $66.5 billion M&A activity with its $20 billion buy of Pharmacyclics; and gastroenterology was one of the most highly partnered therapeutic areas.
Deal Watch: Valeant’s Financial/Commercial Strength Offers A New Chance For Provenge
AstraZeneca buys out respiratory franchise from Actavis, which it had gained a year prior with its purchase of Forest. Mylan announced two deals Feb. 2, collaborating in COPD with Theravance and buying women’s health products from India’s Famy Care.